Early studies suggest a reduced risk of Covid-19 hospitalization when infected with Omicron compared to Delta

“The study is rigorous but it is early (thus might change a bit with more data and more studies will report in the weeks ahead). It should be noted that some South African scientists have been saying Omicron was milder for some time,” Naismith said. “Although two thirds reduction is significant, Omicron can cause severe illness in the doubly vaccinated. Thus, if Omicron continues to double every few days, it could generate many more hospitalisations than Delta from the double vaccinated population.”

The researchers found that the proportion of Omicron cases that were likely reinfections in people who have had Covid-19 before was more than 10 times that of Delta. The data also showed that having received a third dose of vaccine, or booster shot, was associated with a 57% reduction in the risk of symptomatic Omicron infection when compared with being at least 25 weeks out from completing a second dose.

“These early national data suggest that Omicron is associated with a two-thirds reduction in the risk of COVID-19 hospitalisation when compared to Delta. Whilst offering the greatest protection against Delta, the third/booster dose of vaccination offers substantial additional protection against the risk of symptomatic COVID-19 for Omicron,” the researchers wrote in the paper.

The other paper involved data on 161,328 Covid-19 cases reported nationally in South Africa between October 1 and December 6. The researchers — from the National Institute for Communicable Diseases, University of the Witwatersrand and the University of Cape Town — found that among people with Omicron infection, 2.5% were admitted to the hospital during that time compared with 12.8% of people with Delta infection.

The researchers wrote in their paper, “These are early data and findings may change as the epidemic progresses.”

Dr. Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, presented this latest data from South Africa and Scotland at a White House briefing Wednesday — adding that more research is needed to determine if similar results would emerge in the United States.

“In fact, it appears, that in the context of South Africa, there is a decrease in the severity compared to Delta — both in the relationship and ratio between hospitalizations and the number of infections, the duration of hospital stay and the need for supplemental oxygen therapy,” Fauci said Wednesday.

“Recently, literally yesterday, there was another paper that came out from Scotland, which appears to validate and verify the data that are in South Africa,” Fauci said. “This is good news, however, we must wait to see what happens in our own population, which has its own demographic considerations.”

The study, based on data from all PCR-confirmed SARS-CoV-2 cases in England between December 1 and December 14, was conducted by the WHO Collaborating Centre for Infectious Disease Modelling, the MRC Centre for Global Infectious Disease Analysis, Jameel Institute, and Imperial College London. SARS-CoV-2 is the name of the coronavirus that causes Covid-19.

The study estimates the risk of being hospitalized for a day or longer due to the Omicron variant to be 40% to 45% lower than for the Delta variant.

“We find evidence of a reduction in the risk of hospitalization for Omicron relative to Delta infections, averaging over all cases in the study period,” the report states.

“These reductions must be balanced against the larger risk of infection with Omicron, due to the reduction in protection provided by both vaccination and natural infection,” the report cautions. “At a population level, large numbers of infections could still lead to large numbers of hospitalizations.”

The study notes that individuals infected with Omicron after a documented previous infection are 50% to 60% less likely to be hospitalized, compared with people with no previous documented infection.

The report also notes that the risk of hospitalization “is similar for Omicron and Delta for people who test positive for infection and who previously received at least two vaccine doses, reflecting reduced vaccine efficacy against Omicron compared with Delta.”

“However, the risk of hospitalization in vaccinated people remains significantly lower than for unvaccinated people,” adds the report, which has not yet been published in a peer-reviewed journal.

“However, the study suggests there is no reduction in the severity of Omicron compared to Delta for the doubly vaccinated, indicating that it is not milder,” Naismith said. “This finding is surprising but is grounded in data. There is no report on the benefit of boosting.”